EC approves argenx’s efgartigimod alfa for CIDP treatment
The approval is supported by the outcomes from the ADHERE trial.
Drug Development
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Novartis’ ribociclib approved in Canada for early breast cancer
DoH – Abu Dhabi and Sanofi link for vaccine development
Actio gains $66m to advance small molecule therapeutics pipeline
Tisento’s MELAS treatment receives fast track status from FDA
Lisata collaborates with GATC Health on drug development
Averoa secures EC authorisation for oral CKD treatment
